WO2026068794A1 - Auto-anticorps dirigés contre l'anpep pour évaluer le cancer colorectal (ccr) ou un état précancéreux de celui-ci - Google Patents

Auto-anticorps dirigés contre l'anpep pour évaluer le cancer colorectal (ccr) ou un état précancéreux de celui-ci

Info

Publication number
WO2026068794A1
WO2026068794A1 PCT/EP2025/077824 EP2025077824W WO2026068794A1 WO 2026068794 A1 WO2026068794 A1 WO 2026068794A1 EP 2025077824 W EP2025077824 W EP 2025077824W WO 2026068794 A1 WO2026068794 A1 WO 2026068794A1
Authority
WO
WIPO (PCT)
Prior art keywords
anpep
colorectal cancer
antibody
biomarker
precancerous condition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/077824
Other languages
English (en)
Inventor
Wolfgang Koop
Jialing Huang
Tatjana Christina AMMER
Bruno GOLDING
Kai HABBEN
Peter Kastner
Vinzent ROLNY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics International AG
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics International AG
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics International AG, Roche Diagnostics GmbH filed Critical Roche Diagnostics International AG
Publication of WO2026068794A1 publication Critical patent/WO2026068794A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne un procédé d'évaluation du cancer colorectal ou d'un état précancéreux de celui-ci, ledit procédé comprenant a) la détection de la présence ou de l'absence d'un anticorps contre l'ANPEP (aminopeptidase N, un anticorps anti-ANPEP) dans un échantillon de sang, de sérum ou de plasma provenant du sujet, et l'évaluation du cancer colorectal ou de son état précancéreux sur la base de la présence ou de l'absence d'un anticorps contre l'ANPEP déterminé à l'étape a). La présente invention concerne en outre des procédés, des bases de données, des dispositifs, des kits et des utilisations mis en oeuvre par ordinateur associés.
PCT/EP2025/077824 2024-09-30 2025-09-29 Auto-anticorps dirigés contre l'anpep pour évaluer le cancer colorectal (ccr) ou un état précancéreux de celui-ci Pending WO2026068794A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP24203696 2024-09-30
EP24203696.0 2024-09-30

Publications (1)

Publication Number Publication Date
WO2026068794A1 true WO2026068794A1 (fr) 2026-04-02

Family

ID=92932751

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/077824 Pending WO2026068794A1 (fr) 2024-09-30 2025-09-29 Auto-anticorps dirigés contre l'anpep pour évaluer le cancer colorectal (ccr) ou un état précancéreux de celui-ci

Country Status (1)

Country Link
WO (1) WO2026068794A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012028697A1 (fr) 2010-09-01 2012-03-08 Eth Zürich, Institute Of Molecular Biology And Biophysics Système de purification par affinité sur la base d'une complémentation de brin de donneur
US20160178631A1 (en) * 2014-08-22 2016-06-23 Abbott Laboratories Methods for the early detection of colorectal cancer
EP2829881B1 (fr) 2010-07-14 2017-08-23 Commonwealth Scientific and Industrial Research Organisation Diagnostic de cancer colorectal
WO2017153336A1 (fr) 2016-03-07 2017-09-14 F. Hoffmann-La Roche Ag Détection d'anticorps anti-p53

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2829881B1 (fr) 2010-07-14 2017-08-23 Commonwealth Scientific and Industrial Research Organisation Diagnostic de cancer colorectal
WO2012028697A1 (fr) 2010-09-01 2012-03-08 Eth Zürich, Institute Of Molecular Biology And Biophysics Système de purification par affinité sur la base d'une complémentation de brin de donneur
US20160178631A1 (en) * 2014-08-22 2016-06-23 Abbott Laboratories Methods for the early detection of colorectal cancer
WO2017153336A1 (fr) 2016-03-07 2017-09-14 F. Hoffmann-La Roche Ag Détection d'anticorps anti-p53

Non-Patent Citations (44)

* Cited by examiner, † Cited by third party
Title
"Classification of Malignant Tumours", VIRCHOWS ARCH, vol. 472, no. 4, April 2018 (2018-04-01), pages 519 - 531
"UniProt", Database accession no. P02792
"Uniprot", Database accession no. P15144
ASSARSSON ET AL., PLOS ONE, vol. 9, no. 4, 22 April 2014 (2014-04-22)
BARNIEH ET AL.: "Is tumour-expressed aminopeptidase N (APN/CD13) structurally and functionally unique", BBA - REVIEWS ON CANCER, 2021, pages 1876, Retrieved from the Internet <URL:https://doi.org/10.1016/j.bbcan.2021.188641>
BARNIEH ET AL.: "Is tumour-expressed aminopeptidase N (APN/CD13) structurally and functionally unique?", BBA - REVIEWS ON CANCER, 2021, pages 1876, Retrieved from the Internet <URL:https://doi.org/10.1016/j.bbcan.2021.188641>
BHARDWAJ M ET AL., EUROPEAN JOURNAL OF CANCER, vol. 127, 2020, pages 30 - 40
BHARDWAJ M ET AL., MOLECULAR ONCOLOGY, vol. 14, 2019, pages 8 - 21
BRENNER HALTENHOFEN LSTOCK CHOFFMEISTER M., CANCER EPIDEMIOL BIOMARKERS PREV, vol. 22, 2013, pages 1043 - 51
BRENNER HSTOCK CHOFFMEISTER M, BMJ, vol. 348, 2014, pages g2467
BRENNER, D. E.RENNERT, G, CA: A CANCER JOURNAL FOR CLINICIANS, vol. 55, no. 1, 2005, pages 18 - 35
BRENNER, H.TAO, S.HAUG, U: "Blood-based biomarkers for detection of colorectal cancer: A systematic review", CLINICAL EPIDEMIOLOGY, vol. 6, 2014, pages 319 - 331
BRIGGS ET AL.: "Synthesis of Functionalised Fluorescent Dyes and Their Coupling to Amines and Amino Acids", J. CHEM. SOC,PERKIN-TRANS, vol. 1, 1997, pages 1051 - 1058, XP002298160, DOI: 10.1039/a605012c
CARROLL MRSEAMAN HEHALLORAN SP: "Tests and investigations for colorectal cancer screening", CLIN BIOCHEM, vol. 47, 2014, pages 921 - 39, XP028864180, DOI: 10.1016/j.clinbiochem.2014.04.019
DOWDYWEARDEN: "Statistics for Research", 1983, JOHN WILEY & SONS
DUFFY, M. J, CLINICAL CHEMISTRY, vol. 47, no. 4, 2001, pages 624 - 630
FUNG KYNICE EPRIEBE IBELOBRAJDIC DPHATAK APURINS L ET AL.: "Colorectal cancer biomarkers: to be or not to be? Cautionary tales from a road well travelled", WORLD J GASTROENTEROL, vol. 20, 2014, pages 888 - 98
FUNG, K. Y. C.TABOR, B.BUCKLEY, M. J. ET AL.: "Blood-based protein biomarker panel for the detection of colorectal cancer", PLOS ONE, vol. 10, no. 3, 2015, pages e0120425, XP055480791, DOI: 10.1371/journal.pone.0120425
HA ET AL.: "Reduced expression of alanyl aminopeptidase is a robust biomarker of non-familial adenomatous polyposis and non-hereditary nonpolyposis colorectal cancer syndrome early-onset colorectal cancer", CANCER MED, vol. 12, no. 8, April 2023 (2023-04-01), pages 10091 - 10104
HA YE JIN ET AL: "Reduced expression of alanyl aminopeptidase is a robust biomarker of non-familial adenomatous polyposis and non-hereditary nonpolyposis colorectal cancer syndrome early-onset colorectal cancer", vol. 12, no. 8, 1 April 2023 (2023-04-01), GB, pages 10091 - 10104, XP093242721, ISSN: 2045-7634, Retrieved from the Internet <URL:https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cam4.5675> DOI: 10.1002/cam4.5675 *
HASSAN CGIORGI ROSSI PCAMILLONI LREX DKJIMENEZ-CENDALES BFERRONI E ET AL., ALIMENT PHARMACOL THER, vol. 36, 2012, pages 929 - 40
IMPERIALE, T. F., RANSOHOFF, D. F., ITZKOWITZ, S. H., TURNBULL, B. A., & ROSS, M. E., NEW ENGLAND JOURNAL OF MEDICINE, vol. 351, no. 26, 2004, pages 2704 - 2714
LANSDORP-VOGELAAR IKNUDSEN ABBRENNER H., EPIDEMIOL REV, vol. 33, 2011, pages 88 - 100
LENDECKEL ET AL.: "The Role of the Ectopeptidase APN/CD13 in Cancer", BIOMEDICINES, vol. 11, 2023, pages 724, Retrieved from the Internet <URL:https://doi.org/10.3390/biomedicines11030724>
LESLIE ACAREY FAPRATT NRSTEELE RJ., BR J SURG, vol. 89, 2002, pages 845 - 60
LEVIN, B.LIEBERMAN, D. A.MCFARLAND, B ET AL., CA: A CANCER JOURNAL FOR CLINICIANS, vol. 58, no. 3, 2018, pages 130 - 160
LIU, SCAND J IMMUNOL, vol. 91, 2020, pages e12829
N. WILD ET AL: "A Combination of Serum Markers for the Early Detection of Colorectal Cancer", CLINICAL CANCER RESEARCH, vol. 16, no. 24, 26 August 2010 (2010-08-26), US, pages 6111 - 6121, XP055399114, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-10-0119 *
NILOOFA ROSHAN ET AL: "Autoantibodies in the diagnosis, prognosis, and prediction of colorectal cancer", JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol. 17, no. 4, 1 July 2021 (2021-07-01), India, pages 819 - 833, XP093242756, ISSN: 0973-1482, DOI: 10.4103/jcrt.JCRT_64_19 *
OSBORNE JWILSON CMOORE VGREGORY TFLIGHT IYOUNG G.OPEN J, PREV MED, vol. 2, 2012, pages 326 - 31
PANG ET AL.: "Serum APN/CD13 as a novel diagnostic and prognostic biomarker of pancreatic cancer", ONCOTARGET, vol. 7
RAHBAR ET AL.: "Detection of cytotoxic CD13-specific autoantibodies in sera from patients with ulcerative colitis and Crohn's disease", JOURNAL OF AUTOIMMUNITY, vol. 26, 2006, pages 155 - 164, XP024910076, DOI: 10.1016/j.jaut.2006.02.003
RAHBAR ET AL: "Detection of cytotoxic CD13-specific autoantibodies in sera from patients with ulcerative colitis and Crohn's disease", JOURNAL OF AUTOIMMUNITY, LONDON, GB, vol. 26, no. 3, 1 May 2006 (2006-05-01), pages 155 - 164, XP005440002, ISSN: 0896-8411, DOI: 10.1016/J.JAUT.2006.02.003 *
SANZ BEGO�A ET AL: "Aminopeptidase N Activity Predicts 5-Year Survival in Colorectal Cancer Patients", vol. 63, no. 5, 1 June 2015 (2015-06-01), US, pages 740 - 746, XP093242722, ISSN: 1081-5589, Retrieved from the Internet <URL:https://journals.sagepub.com/doi/pdf/10.1097/JIM.0000000000000199> DOI: 10.1097/JIM.0000000000000199 *
SANZ ET AL.: "Aminopeptidase N Activity Predicts 5-Year Survival in Colorectal Cancer Patients", J INVESTIG MED, vol. 63, 2015, pages 740 - 746, XP093242722, DOI: 10.1097/JIM.0000000000000199
SIEGEL RL ET AL.: "Colorectal cancer statistics", CA CANCER J CLIN, vol. 70, no. 3, May 2020 (2020-05-01), pages 145 - 164
SIEGEL, R. L.MILLER, K. D.JEMAL, A, CA: A CANCER JOURNAL FOR CLINICIANS, vol. 70, no. 1, 2020, pages 7 - 30
SODERBERG ET AL., TRANSPLANTATION, vol. 61, no. 4, 1996, pages 594 - 60
SÖDERBERG-NAUCLER ET AL.: "A Novel Mechanism for Virus-Induced Autoimmunity in Humans", IMMUNOLOGICAL REVIEWS
THIRUNAVUKARASU PSUKUMA S: "C-stage in Colon Cancer: Implications of Carcinoembryonic Antigen Biomarker in Staging, Prognosis, and Management", J NATL CANCER INST, vol. 103, 2011, pages 689 - 697
VENKATARAMAN, A.YANG, K.IRIZARRY, J ET AL.: "A toolbox of immunoprecipitation-grade monoclonal antibodies to human transcription factors", NAT METHODS, vol. 15, 2018, pages 330 - 338, Retrieved from the Internet <URL:https://doi.org/10.1038/nmeth.4632>
WILD N ET AL., CLINCANCER RES, vol. 16, no. 24, 15 December 2010 (2010-12-15), pages 6111 - 21
WILD N ET AL.: "A combination of serum markers for the early detection of colorectal cancer", CLINCANCER RES, vol. 16, no. 24, 15 December 2010 (2010-12-15), pages 6111 - 21, XP055399114, DOI: 10.1158/1078-0432.CCR-10-0119
ZWEIG, CLIN. CHEM., vol. 39, 1993, pages 561 - 577

Similar Documents

Publication Publication Date Title
Rho et al. Protein and glycomic plasma markers for early detection of adenoma and colon cancer
US11977077B2 (en) Biomarkers for pancreatic cancer
US10408839B2 (en) Biomarker panel for diagnosing cancer
US20220214345A1 (en) Colorectal cancer screening examination and early detection method
JP2012515335A (ja) 線維症と肝硬変を識別する手段及び方法
US20140271621A1 (en) Methods of prognosis and diagnosis of pancreatic cancer
HK1259001A1 (zh) 癌症的预後和诊断方法
JP4689651B2 (ja) 急性肺塞栓症用生化学マーカー
CN103826662A (zh) 评估急性肾损伤等级的方法和试剂
WO2023284579A1 (fr) COMBINAISON D&#39;ANTICORPS CONTRE LA RÉGÉNÉRATION DE LA PROTÉINE 1α DÉRIVÉE D&#39;ÎLOTS ET KIT DE DÉTECTION LA COMPRENANT
WO2016195051A1 (fr) Panel de biomarqueurs de plasma permettant le diagnostic du cancer du pancréas
EP2906951A1 (fr) Procédé de diagnostic pour cancer colorectal
CN106680515B (zh) 用于肺癌诊断的多分子标志物组合
JP4927825B2 (ja) 初期段階の心機能異常を診断または予測するための装置および方法
KR102018205B1 (ko) 대장암 진단용 조성물 및 상기 조성물을 이용한 대장암 진단 방법
CN117120847A (zh) 肺癌的检测方法
CN116539885B (zh) 用于乳腺癌早期检测的肿瘤自身抗原/抗体组合及应用
EP4533094A1 (fr) Méthodes et systèmes de stratification du risque et de la gestion du cancer de la vessie
CN115372616A (zh) 胃癌相关的生物标志物及其应用
WO2026068798A1 (fr) Sox9 pour évaluer le cancer colorectal (ccr) ou un état précancéreux de celui-ci
WO2026068795A2 (fr) Clec3b pour évaluer le cancer colorectal (crc) ou un état précancéreux de celui-ci
CN117242350A (zh) 用于脓毒症的早期检测的il6标志物组
KR102018209B1 (ko) 위암 진단용 조성물 및 상기 조성물을 이용한 위암 진단 방법
WO2020240011A1 (fr) Méthode de diagnostic du cancer colorectal
US10866239B2 (en) Methods for colon hyperproliferative disorder detection, prognosis, and diagnosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25780164

Country of ref document: EP

Kind code of ref document: A1